Facebook
Twitter
LinkedIn
ForwardMEDISCA Australia | Functional and Personalised Hormone Restoration Therapy: The Fundamentals | 27-28 OCT 2023 (BRISBANE)
MEDISCA Australia
Functional and Personalised Hormone Restoration Therapy: The Fundamentals
This course includes a home study component that serves as a prerequisite to the live activity. Activity participants are required to achieve a 75% passing grade associated with a self-study learning assessment prior to attending the live event.
Full attendance and the completion of a live event learning assessment and evaluation form are a compulsory requirement to achieve credit for the live event.
Compounding hormone therapies and formulations present particular issues and challenges to the compounding pharmacist. The practice-based activity will provide compounding pharmacists with the opportunity to enhance their competency as it relates to the many therapeutic options used in hormone therapies.
Having been presented with a prescription indicating a need for a compounded medication, the participating pharmacist will use uniquely designed patient assessment tools, select appropriate delivery systems for the specific hormones and nutritional supplements prescribed, and then monitor patient progress. During this process the participant will have learned the physiologic features of the hormone systems in the body, how to conduct a patient needs analysis, and then work with physicians to provide pharmacist expertise with respect to the therapeutic, nutritional supplementation, and lifestyle and behavior modification options available to the physician.
Finally, participants will apply monitoring tools and strategies to maintain patient compliance with prescribed therapeutic initiatives. Case work will be documented and clinical findings recorded in a formal manner for purposes of confidential communication, record keeping and statistical analysis.
Intended audience
Physicians, pharmacists and nurse practitioners engaged in prescription hormone practice.
Learning Objectives
OVERALL LEARNING OBJECTIVES OF SELF-STUDY ACTIVITY
- Describe the hormone cascade.
- Describe the relative distribution of hormones in the body.
- Learn the physiological basis of hormone therapy.
- Learn the general hormone system functions; gonadal, adrenal and thyroid.
- Explain the female and male reproductive hormone system lifecycles.
- Review signs of female and male hormone imbalances.
- Describe principles of hormone functioning, relationships, and imbalance.
- Review test types, their advantages and disadvantages, used in hormone therapy.
- Review hormone therapy-related evidence-based medicine abstracts and citations.
OVERALL LEARNING OBJECTIVES OF LIVE ACTIVITY
- Evaluate and apply a unique set of rules applicable to customised hormone restoration therapy.
- Analyse physiological and biochemical features of endocrine system dysfunctions.
- Describe the hormone cascade, its neurobiological communication network, effects of exogenous and endogenous factors on the cascade, and impact on endocrine and neighbouring digestive and immune systems.
- Investigate and evaluate therapeutic alternatives for specific classifications related to hormone therapy and imbalance; specifically construct formulations, which may be prescribed or used by a healthcare provider in the treatment of perimenopause, menopause, andropause, thyroid dysfunction, adrenal dysfunction, metabolic syndrome, and sexual dysfunction.
- Interpret, integrate, and evaluate comprehensive patient assessment chart data; including prior medical history, familial history, differential diagnoses, lifestyle behaviours, signs and symptoms, and laboratory test results.
- Describe and design hormone-related medication options, adjunct pharmacotherapeutics, and nutraceutical treatments that are optimal and efficacious for the individual patient.
- Recognize and evaluate the various routes of delivery, delivery systems, dosage, forms and dispensing mechanisms used in hormone therapy, adjunct therapy, nutraceutical supplementation, and specific aspects of lifestyle management; and monitor patient responses through quantitative and qualitative systematic testing.
Wednesday & Thursday 1 - 2 November, 8am-5pm
Doors open from 7:30am
DAY 1 | ||
8:00AM – 8:15AM | Orientation/Introduction | |
8:15AM – 9:30AM | SECTION 1 : Fundamental Principals and Rules of Engagement | Restoration and Balance |
Relative Versus Absolute | ||
Balance and Relative Sensitivity | ||
Free versus Bound | ||
Up and Down Regulation | ||
Additive, Synergistic, and Antagonistic Activity | ||
Pharmacokinetic versus Pharmacodynamic Balance | ||
Cyclic versus Continuous Dosing | ||
Routes of Delivery and Delivery Systems | ||
Monitoring Frequency and Therapeutic Intent | ||
Minimum Dose for Maximum Effect | ||
Philosophical Guideline | ||
9:30AM – 10:45AM | SECTION 2 : Hormones and Hormone System Functions
| When Harry met Sally |
Hierarchical Function and the Hormone Cascade | ||
Influence of Exogenous Factors and Disease | ||
The Endocrine Organs | ||
The Hypothalamic-Pituitary-Gonadal Axis | ||
Menstrual Cycle Phases | ||
Menstrual Cycle Hormones | ||
Abnormal Menstrual Cycle | ||
Sally's Daughter Brittany | ||
Sally in Perimenopause | ||
Specific Symptoms of Hormone Imbalances in Females | ||
10:45AM – 11:05AM | Morning Tea | |
11:05AM – 11:45AM | SECTION 3 : Evaluating the Risk of Female Hormone Restoration
| Sally and Susie in a State of Disrepair |
Synthetic versus Bioidentical | ||
Oral versus Transdermal | ||
Estrogen Types, Binding, and Dosing | ||
Androgen Therapy | ||
North American Menopause Society | ||
11:45AM – 12:30PM | SECTION 4 : Subjective and Objective Testing
| Depression and Symptom Bias |
Assessment Algorithm | ||
Case Assessment Design and Instructions | ||
Hormone Testing | ||
Hormone Testing and Route of Delivery | ||
Caution regarding Normative Databases | ||
Pausing Medication for Testing | ||
12:30PM – 1:15PM | Lunch | |
1:15PM – 1:35PM | SECTION 5 : Inter-Hormone Relationships |
|
1:35PM – 2:45PM | SECTION 6 : Adrenal Function and Dysfunction | Sally has succumbed to Fatigue |
General Adaption Model | ||
Cortisol | ||
Specific Symptoms of Hormone Imbalances in Females | ||
Progesterone Steal | ||
Low Androgen in Females | ||
High Androgen in Females | ||
Adrenal Hypofunction | ||
2:45PM – 3:05PM | Afternoon Tea | |
3:05PM – 3:50PM | SECTION 7: Adjunct Nutraceutical Therapy | Nutraceuticals |
Quality Concerns | ||
Nutraceutical Functions and Recommended Dosages | ||
3:50PM – 5:00PM | SECTION 8: Special Considerations Related to Treatment Protocols | Life Cycle Related Considerations |
Non-Ovulation Premenopausal Circumstance Considerations | ||
Pregnancy and Lactation Related Considerations | ||
Cancer Risk Related Considerations | ||
Lifestyle Related Considerations | ||
DAY 2 | ||
8:00AM – 9:30AM | SECTION 9 : Treatment Protocols for Male Hypogonadism and Male Sexual Dysfunction
| Treatment Protocol for Premenstrual Syndrome |
Treatment Protocol for Perimenopause | ||
Treatment Protocol for Natural Menopause | ||
Treatment Protocol for Surgical Menopause | ||
Treatment Protocol: Bi-Est Strength & Percentages | ||
Inter-Hormone Relationships and Ovarian Function | ||
Case Study 1 | ||
9:30AM – 11:00AM | SECTION 10 : Male Hypogonadism and Sexual Dysfunction
| The Challenge |
Specific Symptoms of Hormone Imbalances in Males | ||
Treatment Protocol for Andropause | ||
Treatment Protocol for Hypogonadism | ||
Treatment Protocol for Erectile Dysfunction | ||
Case Study 2 | ||
11:00AM – 11:20AM | Morning Tea | |
11:20AM – 12:20PM | Section 11 : Thyroid Function and Dysfunction | Sally – Thyroid or Adrenal Dysfunction |
The Hypothalamic-Pituitary-Thyroid (HPT) Axis | ||
Thyroid Hormone Metabolism | ||
Inter-Hormone Relationships and Thyroid Function | ||
Thyroid Dysfunctions | ||
Case Study 3 | ||
12:20PM – 1:00PM | SECTION 12 : Female Sexual Dysfunction
| Harry and Sally |
Vulvar and Vaginal Atrophy | ||
Vulvodynia | ||
Case Study 4 | ||
1:00PM – 1:45PM | Lunch | |
1:45PM – 3:00PM | SECTION 13 : Strategies for Treatment Modification
| Detoxification from Excessive Hormone Therapy |
End of Treatment Strategy - Female | ||
End of Treatment Strategy - Male | ||
Harry and Sally in their Later Years | ||
Case Study 5.1 | ||
Case Study 5.2 | ||
3:00PM – 3:20PM | Afternoon Tea | |
3:20PM – 4:00PM | SECTION 14 : Route of Delivery, Dosage Form and Delivery System | Route of Delivery |
Dosage Form | ||
Delivery System | ||
Delivery Device | ||
Special Considerations | ||
4:00PM – 5:00PM | SECTION 15 : PCOS, Metabolic Syndrome, and Insulin Resistance | Polycystic Ovary Syndrome |
Metabolic Syndrome | ||
Case Study 6 | ||
Please call the hotel directly to book accommodation. Quote the 'Medisca Seminar (27-28 October)' for the conference rate.
| TARA D. SCOTT, MD, FACOG, FAAFM, ABOIM, NCMP Facilitator, LP3 Network; Fellow of American College of OB/GYN; Advanced Fellow and certified in Anti-aging, Regenerative, and Functional Medicine; Board Certified, American Board of Integrative Medicine, Certified Menopause Practitioner, North American Menopause Society; Clinical Associate Professor of OB/GYN, Northeast Ohio Medical University; Chief Medical Officer, Revitalize Medical Group; Medical Director of Integrative Medicine, Summa Health Systems Disclosure: None |  |
Dr. Tara Scott graduated from Northeast Ohio University College of Medicine and completed her residency with Summa Health Systems at Akron City Hospital in Ohio. She recently retired from OB/GYN after almost 20 years to focus on functional and integrative medicine. She is a Clinical Associate Professor at Northeast Ohio Medical University, where she teaches residents and is involved in clinical research.
Dr. Scott is a certified menopause practitioner with the North American Menopause Society and a fellow of the American College of Obstetrics and Gynecology. She first became involved with hormone and integrative medicine while practicing as an OB/GYN. Her empathy for patients experiencing hormone-related issues led her to become trained as an advanced fellow and certified by the American Academy of Anti-Aging Medicine. The evidence-based practices she employed helped many patients conquer chronic wellness issues. She then started Revitalize Medical Group, where she serves as the Chief Medical Officer. In 2016, she obtained an additional board certification in Integrative Medicine. Recently, Dr. Scott was appointed as Medical Director for Summa Health in Akron, Ohio, where she will develop and run an Integrative Medicine program. Dr. Scott is passionate about educating the medical community on the advances in evidence-based hormone therapy. She lectures around the community to raise awareness about wellness and hormone balance.
KEN SPEIDEL, BS Pharm, PharmD, RPh, FIACP, FACA |  |
Dr. Ken Speidel is recognized for his broad experience in pharmacy practice and education, including his national recognition as a pharmacotherapeutic specialist in endocrinology and pain management. In addition, Dr. Speidel provides expert training in sterile and non-sterile compounding processes in the acute care, community, outpatient, and 503A/503B practice sectors. He has been instrumental in the development of national standards for pharmacy compounding practices and provides consulting services to many organizations, including boards of pharmacy as well as hospitals and health systems in the United States and abroad.
In addition to his worldwide consulting and educational work, Dr. Speidel is a retired Professor of Pharmacy Practice from the University of Findlay. He has also assisted in the development and facilitation of many nationally recognized educational programs, approved by the Accreditation Council for Pharmacy Education (ACPE). Moreover, Dr. Speidel was an advisor for the development of the Pharmacy Compounding Accreditation Board (PCAB) and remains a surveyor and accreditation expert for PCAB/ACHC (Accreditation Commission for Health Care). Dr. Speidel has served as multi-term president of the National Home Infusion Association (NHIA) as well as president of the Hospice of Portage, a large hospice program in the United States.
Dr. Speidel received a Bachelor of Science and Doctor of Pharmacy from Ohio Northern University and has completed postdoctoral training in nutritional support and functional medicine. He has been awarded Fellowship status with the International Academy of Compounding Pharmacists (IACP) as well as the American College of Apothecaries (ACA).
A2210MED1
This activity has been accredited for 21 hours of Group 1 CPD (or 21 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 21 hours of Group 2 CPD (or 42 CPD credits) upon successful completion of relevant assessment activities.
Pharmacist Competencies: 1.1, 1.2, 1.3, 1.4, 1.5, 3.1, 3.2, 3.4, 3.5
| The 2016 Competency Standards addressed by this activity include | |
| 1.1 | Uphold professionalism in practice |
| 1.2 | Observe and promote ethical standards |
| 1.3 | Practise within applicable legal framework |
| 1.4 | Maintain and extend professional practice |
| 1.5 | Apply expertise in professional practice |
| 3.1 | Develop a patient centred, culturally responsive approach to medication management |
| 3.2 | Implement the medication management strategy or plan |
| 3.4 | Compound medicines |
| 3.5 | Support Quality Use of Medicines |
CANCELLATION AND REFUND POLICY
In the event that MEDISCA Australia cancels a course, MEDISCA Australia’s sole liability shall be course repayment. In no event shall MEDISCA Australia be responsible for any costs arising from such cancellation, including but not limited to travel and/or accommodation.In the event a Registrant cancels their enrollment in a CPD Activity, a written request must be sent to MEDISCA Australia requesting ‘Cancellation without Transfer’ to an alternate live CPD Activity event date. If cancellation occurs at greater than or equal to 31 days from live activity event date, then registrant will receive a 75% refund; 15-30 days a 50% refund; and less than or equal to 14 days no refund. MEDISCA Australia shall be excused from any delay caused by reason of any occurrence or contingency beyond its reasonable control (a “Force Majeure”), including but not limited to, acts of God, hurricane, earthquake, labour disputes, strikes, riots, war, and governmental requirements. The obligation to pay money to MEDISCA Australia in a timely manner is absolute and shall not be subject to this Force Majeure provision. In such event, MEDISCA Australia will not issue any refunds, only transfer to an alternate live activity event date.This cancellation and refund policy is specific to courses offered in Australia. To obtain information on the cancellation and refund policy for courses offered outside of Australia, please speak to a MEDISCA Australia representative or refer to your course-specific registration page.
TRANSFER POLICY - AUSTRALIA COURSES ONLY
This transfer policy is only applicable to courses that are offered in Australia. Transfer policy is only in effect if requested greater than or equal to 14 days prior to the original live activity event date. Failure to submit “Transfer Request” at least 14 days prior to original live activity event date will default to “Cancellation and Refund Policy”. Transfer policy can only apply one (1) time. Transfer to a new live event date must be within current calendar year. Failure to attend the new live activity event will lead to no refund and will no longer be transferable. Confirmation of new activity date is subject to the approval by MEDISCA Australia based on the number of available seats within the selected live activity event.
Price
CANCELLATION AND REFUND POLICY
In the event that MEDISCA Australia cancels a course, MEDISCA Australia’s sole liability shall be course repayment. In no event shall MEDISCA Australia be responsible for any costs arising from such cancellation, including but not limited to travel and/or accommodation. In the event a Registrant cancels their enrollment in a CPD Activity, a written request must be sent to MEDISCA Australia requesting ‘Cancellation without Transfer’ to an alternate live CPD Activity event date. If cancellation occurs at greater than or equal to 31 days from live activity event date, then registrant will receive a 75% refund; 15-30 days a 50% refund; and less than or equal to 14 days no refund. MEDISCA Australia shall be excused from any delay caused by reason of any occurrence or contingency beyond its reasonable control (a “Force Majeure”), including but not limited to, acts of God, hurricane, earthquake, labour disputes, strikes, riots, war, and governmental requirements. The obligation to pay money to MEDISCA Australia in a timely manner is absolute and shall not be subject to this Force Majeure provision. In such event, MEDISCA Australia will not issue any refunds, only transfer to an alternate live activity event date. This cancellation and refund policy is specific to courses offered in Australia. To obtain information on the cancellation and refund policy for courses offered outside of Australia, please speak to a MEDISCA Australia representative or refer to your course-specific registration page.
TRANSFER POLICY – AUSTRALIA COURSES ONLY
This transfer policy is only applicable to courses that are offered in Australia. Transfer policy is only in effect if requested greater than or equal to 14 days prior to the original live activity event date. Failure to submit “Transfer Request” at least 14 days prior to original live activity event date will default to “Cancellation and Refund Policy”. Transfer policy can only apply one (1) time. Transfer to a new live event date must be within current calendar year. Failure to attend the new live activity event will lead to no refund and will no longer be transferable. Confirmation of new activity date is subject to the approval by MEDISCA Australia based on the number of available seats within the selected live activity event.